@inbook{23d68655f0f941c3a96cef98092a13e5,
title = "Recombinant vectors as influenza vaccines",
abstract = "The antiquated system used to manufacture the currently licensed inactivated influenza virus vaccines would not be adequate during an influenza virus pandemic. There is currently a search for vaccines that can be developed faster and provide superior, long-lasting immunity to influenza virus as well as other highly pathogenic viruses and bacteria. Recombinant vectors provide a safe and effective method to elicit a strong immune response to a foreign protein or epitope. This review explores the advantages and limitations of several different vectors that are currently being tested, and highlights some of the newer viruses being used as recombinant vectors.",
author = "Kopecky-Bromberg, {Sarah A.} and Peter Palese",
note = "Funding Information: Work done in the laboratory of the authors was funded by NIH grants U54 AI057158 (Northeast Biodefense Center) and U01 AI070469 (Live Attenuated Vaccines for Epidemic and Pandemic Flu), and with Bill and Melinda Gates Foundation grant 38648.",
year = "2009",
doi = "10.1007/978-3-540-92165-3_13",
language = "English",
isbn = "9783540921646",
series = "Current Topics in Microbiology and Immunology",
publisher = "Springer Verlag",
number = "1",
pages = "243--267",
booktitle = "Vaccines for Pandemic Influenza",
address = "Germany",
edition = "1",
}